Quick answer: latest quarter results, by ticker or company name

Reported Q: Q1 2025 Rev YoY: -81.5% EPS YoY: +39.7% Move: -6.80%

uniQure NV

0EE0.L

$14.64 -6.80%

Exchange LSE Sector Healthcare Industry Medical Pharmaceuticals

Q1 2025

Published: May 9, 2025

Company Status Snapshot

Fast view of the latest quarter outcome for 0EE0.L

Reported

Report Date

May 9, 2025

Quarter Q1 2025

Revenue

1.57M

YoY: -81.5%

EPS

-0.82

YoY: +39.7%

Market Move

-6.80%

Previous quarter: Q4 2024

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Revenue of $1.57M down 81.5% year-over-year
EPS of $-0.82 increased by 39.7% from previous year
Gross margin of 87.4%
Net income of -43.64M
"Our strategic focus is achieving milestone results in our clinical trials, as they are crucial for driving revenues in the future." - CEO

0EE0.L

uniQure NV

Period Q1 2025

Currency USD

Report Type Quarterly Earnings

Generated Mar 27, 2026

Swipe to view all report sections

Executive Summary

In Q1 2025, uniQure NV reported significant revenue challenges with total revenues of $1.567 million, marking an 81.53% year-over-year decline and a staggering 69.99% decline quarter-over-quarter. However, the company maintained a strong gross profit ratio of 87.43%, reflecting effective cost management amidst a pivotal phase of transitioning its clinical pipeline. Their net loss widened to $43.637 million due to increased operational costs, primarily in research and development (R&D) which amounted to $36.14 million.

Despite setbacks in revenue, uniQure continues to invest heavily in advancing its gene therapy portfolio, particularly focusing on its key programs such as Etranacogene dezaparvovec for hemophilia B and AMT-130 for Huntington's disease. Investors should watch the progress of these clinical trials as successful outcomes could revitalize revenue streams in the near future.

Key Performance Indicators

Revenue

Decreasing

1.57M

QoQ: -69.99% | YoY: -81.53%

Gross Profit

Increasing

1.37M

87.43% margin

QoQ: -70.23% | YoY: 140.65%

Operating Income

Increasing

-39.33M

QoQ: 14.18% | YoY: 28.96%

Net Income

Increasing

-43.64M

QoQ: 40.44% | YoY: 33.50%

EPS

Increasing

-0.82

QoQ: 45.70% | YoY: 39.71%

Revenue Trend

Margin Analysis

Financial Highlights

### Revenue Performance
- Total Revenue: $1.567 million, down 81.53% YoY and 69.99% QoQ.
- Gross Profit: $1.37 million, a 140.65% YoY increase indicating improved operational efficiency despite reduced revenues.

### Profitability
- Operating Income: -$39.331 million, a slight improvement (14.18% QoQ), yet highlights ongoing pressure on profitability.
- Net Income: -$43.637 million, which reflects a 33.50% YoY reduction in losses.

### Cash Flow and Balance Sheet
- Net Cash Used In Operations: -$44.1 million, showing high cash burn typical of R&D-intensive firms.
- Cash and Cash Equivalents: $217.229 million, with a current ratio of 11.99 highlighting robust liquidity.

### Investment Metrics
- Debt Ratios: Total debt to capitalization ratio stands at 66.3%, indicating a high leverage situation, which investors must monitor closely.

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	1.57M	-81.53%	-69.99%
Gross Profit	1.37M	140.65%	-70.23%
Operating Income	-39.33M	28.96%	14.18%
Net Income	-43.64M	33.50%	40.44%
EPS	-0.82	39.71%	45.70%

Key Financial Ratios

Gross Profit Margin

Excellent

87.40%

Gross profit margin is exceptional, indicating strong pricing power and operational efficiency

Operating Profit Margin

Weak

-25.10%

Operating margin is below industry norms, profitability concerns

Net Profit Margin

Weak

-27.85%

Net profit margin is below industry norms, profitability concerns

Return on Assets

Weak

-0.07%

Return on assets suggests inefficient capital allocation

Return on Equity

Weak

-1.30%

Return on equity suggests inefficient capital allocation

Current Ratio

Strong

11.99

Current ratio indicates excellent liquidity and financial flexibility

Debt to Equity

High Risk

1.97

Debt-to-equity indicates high leverage and elevated financial risk

P/E Ratio

Negative

-3.23x

Negative earnings make P/E ratio not meaningful

Price to Book

High Premium

16.71x

Very high premium suggests asset-light business model or lofty expectations

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q3 2025	3.70	-1.38	+61.8%	View
Q2 2025	5.26	-0.69	-52.7%	View
Q1 2025	1.57	-0.82	-81.5%	View
Q4 2024	5.22	-1.51	-22.0%	View
Q3 2024	2.29	-0.91	+62.5%	View

0EE0.L

uniQure NV

Q3 2025 Report

uniQure NV (0EE0.L) QQ3 2025 Results Analysis – Early Pipeline Catalysts with Ongoing R&D Burn in a Pre-Commercial Gene Therapy Company...

Read full report

0EE0.L

uniQure NV

Q2 2025 Report

uniQure NV (0EE0.L) Q2 2025 Financial Results: A Steadfast Path Through Challenges Amid Innovative Growth...

Read full report

0EE0.L

uniQure NV

Q4 2024 Report

uniQure NV (0EE0.L) Q4 2024 Financial Results: Navigating Challenges as Development Progresses...

Read full report

0EE0.L

uniQure NV

Q3 2024 Report

uniQure NV (0EE0.L) Q3 2024 Financial Analysis - Navigating Through Challenges with Strong R&D Commitment...

Read full report

uniQure NV (0EE0.L) Q1 2025 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Historical Earnings Comparison

More 0EE0.L Quarterly Reports

0EE0.L

0EE0.L

0EE0.L

0EE0.L

Related Financial Data

Sector Analysis: Healthcare

0EE0.L Full Profile

0EE0.L Financial Statements

Earnings Calendar